NG 004
Alternative Names: Anti-Nogo-A antibodies - NovaGo Therapeutics; NG-004Latest Information Update: 17 Feb 2025
At a glance
- Originator NovaGo Therapeutics
- Class Eye disorder therapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Nogo protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Spinal cord injuries
- Discontinued Diabetic retinopathy; Stroke
Most Recent Events
- 18 Dec 2024 Phase-I clinical trials in Spinal cord injuries in Germany (Intrathecal) (NCT06817577)
- 18 Dec 2024 Phase-I clinical trials in Spinal cord injuries in Switzerland (Intrathecal) (NCT06817577)
- 07 Dec 2022 NG 004 is still in preclinical trials for Spinal cord injuries in Switzerland (Neurimmune Therapeutics pipeline, December 2022)